ID   U-87MG ATCC
AC   CVCL_0022
SY   U-87MG; U-87 MG; U87 MG; U-87-MG; U87-MG; U87MG; U-87; U87; 87 MG; 87MG
DR   BTO; BTO:0002036
DR   CLO; CLO_0009463
DR   CLO; CLO_0009464
DR   EFO; EFO_0005237
DR   MCCL; MCC:0000469
DR   CLDB; cl4592
DR   CLDB; cl4594
DR   CLDB; cl4595
DR   CLDB; cl7166
DR   Abcam; ab278079
DR   AddexBio; C0005002/71
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-14
DR   BCRC; 60360
DR   BCRJ; 0241
DR   BioGRID_ORCS_Cell_line; 348
DR   BioSample; SAMN03472715
DR   BioSample; SAMN03473126
DR   BioSample; SAMN05292456
DR   BioSample; SAMN07710026
DR   BioSample; SAMN07710027
DR   BioSample; SAMN07710028
DR   BioSample; SAMN07710029
DR   BioSample; SAMN07710030
DR   BioSample; SAMN07710031
DR   BioSample; SAMN07710032
DR   BioSample; SAMN10988360
DR   cancercelllines; CVCL_0022
DR   CCRID; 1101HUM-PUMC000208
DR   CCRID; 3101HUMTCHu138
DR   CCTCC; GDC0157
DR   Cell_Model_Passport; SIDM01189
DR   CGH-DB; 157-1
DR   ChEMBL-Cells; CHEMBL3307575
DR   ChEMBL-Cells; CHEMBL3989361
DR   ChEMBL-Targets; CHEMBL614247
DR   CLS; 300367
DR   Cosmic; 687590
DR   Cosmic; 849853
DR   Cosmic; 850741
DR   Cosmic; 850822
DR   Cosmic; 920816
DR   Cosmic; 1036336
DR   Cosmic; 1064099
DR   Cosmic; 1066234
DR   Cosmic; 1171224
DR   Cosmic; 1175825
DR   Cosmic; 1198263
DR   Cosmic; 1217671
DR   Cosmic; 1219449
DR   Cosmic; 1237542
DR   Cosmic; 1294951
DR   Cosmic; 1610737
DR   Cosmic; 1746951
DR   Cosmic; 1945859
DR   Cosmic; 2302316
DR   Cosmic; 2367555
DR   Cosmic; 2491106
DR   Cosmic; 2516044
DR   Cosmic; 2550364
DR   Cosmic; 2568870
DR   Cosmic; 2580918
DR   Cosmic; 2701083
DR   Cosmic-CLP; 687590
DR   DepMap; ACH-000075
DR   ECACC; 89081402
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS424ENC
DR   GDSC; 687590
DR   GEO; GSM101687
DR   GEO; GSM101688
DR   GEO; GSM101676
DR   GEO; GSM101686
DR   GEO; GSM326243
DR   GEO; GSM481417
DR   GEO; GSM500897
DR   GEO; GSM887723
DR   GEO; GSM888817
DR   GEO; GSM923437
DR   GEO; GSM1374974
DR   GEO; GSM1638668
DR   GEO; GSM1670559
DR   GEO; GSM2113436
DR   GEO; GSM2113437
DR   GEO; GSM2113438
DR   GEO; GSM2113439
DR   HIVReagentProgram; ARP-2188
DR   IARC_TP53; 21096
DR   IBRC; C10982
DR   ICLC; HTL00013
DR   IZSLER; BS TCL 189
DR   KCB; KCB 2011101YJ
DR   KCLB; 30014
DR   LiGeA; CCLE_552
DR   LINCS_HMS; 50868
DR   LINCS_LDP; LCL-1364
DR   Lonza; 37
DR   Lonza; 808
DR   NCBI_Iran; C531
DR   PharmacoDB; U87MG_1623_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD000661
DR   PRIDE; PXD001565
DR   PRIDE; PXD003790
DR   Progenetix; CVCL_0022
DR   PubChem_Cell_line; CVCL_0022
DR   RCB; RCB0419
DR   TOKU-E; 3381
DR   Ubigene; YC-C028
DR   Wikidata; Q7863603
RX   PubMed=327080;
RX   PubMed=450131;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=7459858;
RX   PubMed=7763724;
RX   PubMed=8069455;
RX   PubMed=9090379;
RX   PubMed=9230885;
RX   PubMed=9842975;
RX   PubMed=10074188;
RX   PubMed=10402232;
RX   PubMed=10416987;
RX   PubMed=10560660;
RX   PubMed=11414198;
RX   PubMed=11416159;
RX   PubMed=11966317;
RX   PubMed=14614447;
RX   PubMed=14655754;
RX   PubMed=14961077;
RX   PubMed=16232199;
RX   PubMed=16697959;
RX   PubMed=17595512;
RX   PubMed=19365568;
RX   PubMed=19435942;
RX   PubMed=20126413;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20587068;
RX   PubMed=20593219;
RX   PubMed=21406405;
RX   PubMed=22282976;
RX   PubMed=22460905;
RX   PubMed=22570425;
RX   PubMed=23325432;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=26496030;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27412690;
RX   PubMed=27582061;
RX   PubMed=27894925;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=33385022;
WW   https://en.wikipedia.org/wiki/U87
WW   https://www.atcc.org/en/support/technical-support/faqs/atcc-htb-14-morphology-and-growth-conditions
WW   https://www.synapse.org/#!Synapse:syn31544489
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=58
WW   https://www.proteinatlas.org/learn/cellines
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/U-87_Myers_protocol.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/u/cell-lines-detail-314.html
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535.
CC   Population: Caucasian.
CC   Doubling time: 39 hours (PubMed=9842975); 72 hours (PubMed=25984343); ~34 hours (PBCF).
CC   HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,13:07 (PubMed=25960936).
CC   HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293).
CC   HLA typing: A*02:01:01; B*44:02; C*05:01:01 (PubMed=27412690).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=9090379; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap).
CC   Omics: Cell surface proteome.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.69%; Native American=0%; East Asian, North=3.92%; East Asian, South=0%; South Asian=0%; European, North=72.18%; European, South=23.21% (PubMed=30894373).
CC   Discontinued: RCB; RCB0419; true.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=11416159; PubMed=22570425; PubMed=25877200; PubMed=27582061
ST   Amelogenin: X (AddexBio; CCRID; CLS; ECACC; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=22570425; PubMed=25877200; PubMed=27582061)
ST   Amelogenin: X,Y (ATCC; Cosmic-CLP; KCLB)
ST   CSF1PO: 10,11
ST   D10S1248: 14
ST   D12S391: 18,21
ST   D13S317: 8,11
ST   D16S539: 12
ST   D18S51: 13 (CLS; PubMed=22570425)
ST   D18S51: 13,14 (CCRID; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=25877200)
ST   D19S433: 15,15.2
ST   D1S1656: 15
ST   D21S11: 28,32.2
ST   D22S1045: 15,17
ST   D2S1338: 20,23
ST   D2S441: 10,11
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 8,9
ST   D8S1179: 10,11
ST   FGA: 18,24
ST   Penta D: 9,14
ST   Penta E: 7,14
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=450131; DOI=10.1038/279797a0;
RA   Day R.S. III, Ziolkowski C.H.J.;
RT   "Human brain tumour cell strains with deficient host-cell reactivation
RT   of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.";
RL   Nature 279:797-799(1979).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7763724;
RA   Satoh M., Takeuchi M.;
RT   "Cross-contamination of cell lines as revealed by DNA fingerprinting
RT   in the IFO animal cell bank.";
RL   Res. Commun. Inst. Ferment. Osaka 16:18-23(1993).
//
RX   PubMed=8069455; DOI=10.1007/BF02631450;
RA   Fukuchi K.-i., Hearn M.G., Deeb S.S., Smith A.C., Ngoc Thao D.,
RA   Miyazaki J.-i., Bothwell M., Martin G.M.;
RT   "Activity assays of nine heterogeneous promoters in neural and other
RT   cultured cells.";
RL   In Vitro Cell. Dev. Biol. Anim. 30:300-305(1994).
//
RX   PubMed=9090379; DOI=10.1038/ng0497-356;
RA   Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H.,
RA   Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T.,
RA   Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.;
RT   "Identification of a candidate tumour suppressor gene, MMAC1, at
RT   chromosome 10q23.3 that is mutated in multiple advanced cancers.";
RL   Nat. Genet. 15:356-362(1997).
//
RX   PubMed=9230885; DOI=10.1093/jnci/89.14.1036;
RA   Gomez-Manzano C., Fueyo J., Kyritsis A.P., McDonnell T.J., Steck P.A.,
RA   Levin V.A., Yung W.-K.A.;
RT   "Characterization of p53 and p21 functional interactions in glioma
RT   cells en route to apoptosis.";
RL   J. Natl. Cancer Inst. 89:1036-1044(1997).
//
RX   PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z;
RA   Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N.,
RA   Krajewski S., Reed J.C., von Deimling A., Dichgans J.;
RT   "Predicting chemoresistance in human malignant glioma cells: the role
RT   of molecular genetic analyses.";
RL   Int. J. Cancer 79:640-644(1998).
//
RX   PubMed=10074188; DOI=10.1128/JVI.73.4.3338-3350.1999;
RA   Arbour N., Cote G., Lachance C., Tardieu M., Cashman N.R.,
RA   Talbot P.J.;
RT   "Acute and persistent infection of human neural cell lines by human
RT   coronavirus OC43.";
RL   J. Virol. 73:3338-3350(1999).
//
RX   PubMed=10402232; DOI=10.3892/ijo.15.2.237;
RA   Sharif T.R., Sharif M.;
RT   "Overexpression of protein kinase C epsilon in astroglial brain tumor
RT   derived cell lines and primary tumor samples.";
RL   Int. J. Oncol. 15:237-243(1999).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=10560660; DOI=10.1097/00005072-199911000-00007;
RA   Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L.,
RA   Collins V.P.;
RT   "Mutational profile of the PTEN gene in primary human astrocytic
RT   tumors and cultivated xenografts.";
RL   J. Neuropathol. Exp. Neurol. 58:1170-1183(1999).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11966317; DOI=10.1667/0033-7587(2002)157[0516:LDRHIH]2.0.CO;2;
RA   Chandna S., Dwarakanath B.S.R., Khaitan D., Mathew T.L., Jain V.;
RT   "Low-dose radiation hypersensitivity in human tumor cell lines:
RT   effects of cell-cell contact and nutritional deprivation.";
RL   Radiat. Res. 157:516-525(2002).
//
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
//
RX   PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x;
RA   Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.;
RT   "P-glycoprotein and multidrug resistance-associated protein mediate
RT   specific patterns of multidrug resistance in malignant glioma cell
RT   lines, but not in primary glioma cells.";
RL   Brain Pathol. 13:482-494(2003).
//
RX   PubMed=14961077; DOI=10.1038/sj.onc.1207244;
RA   Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S.;
RT   "p53 disruption profoundly alters the response of human glioblastoma
RT   cells to DNA topoisomerase I inhibition.";
RL   Oncogene 23:1283-1290(2004).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=16697959; DOI=10.1016/j.ccr.2006.03.030;
RA   Lee J., Kotliarova S., Kotliarov Y., Li A.-G., Su Q., Donin N.M.,
RA   Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K.,
RA   Fine H.A.;
RT   "Tumor stem cells derived from glioblastomas cultured in bFGF and EGF
RT   more closely mirror the phenotype and genotype of primary tumors than
RT   do serum-cultured cell lines.";
RL   Cancer Cell 9:391-403(2006).
//
RX   PubMed=17595512; DOI=10.1159/000104150;
RA   Rieger J., Frank B., Weller M., Wick W.;
RT   "Mechanisms of resistance of human glioma cells to Apo2
RT   ligand/TNF-related apoptosis-inducing ligand.";
RL   Cell. Physiol. Biochem. 20:23-34(2007).
//
RX   PubMed=19365568; DOI=10.1371/journal.pone.0005209;
RA   Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L.,
RA   Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A.,
RA   Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D.J., Hargrave D.,
RA   Jones C.;
RT   "Molecular and phenotypic characterisation of paediatric glioma cell
RT   lines as models for preclinical drug development.";
RL   PLoS ONE 4:E5209-E5209(2009).
//
RX   PubMed=19435942; DOI=10.1215/15228517-2009-025;
RA   Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R.,
RA   Jones D.T.W., Collins V.P.;
RT   "IDH1 mutations are present in the majority of common adult gliomas
RT   but rare in primary glioblastomas.";
RL   Neuro-oncol. 11:341-347(2009).
//
RX   PubMed=20126413; DOI=10.1371/journal.pgen.1000832;
RA   Clark M.J., Homer N., O'Connor B.D., Chen Z.-G., Eskin A., Lee H.,
RA   Merriman B., Nelson S.F.;
RT   "U87MG decoded: the genomic sequence of a cytogenetically aberrant
RT   human cancer cell line.";
RL   PLoS Genet. 6:E1000832-E1000832(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20587068; DOI=10.1186/1471-2407-10-339;
RA   Nakabayashi H., Yawata T., Shimizu K.;
RT   "Anti-invasive and antiangiogenic effects of MMI-166 on malignant
RT   glioma cells.";
RL   BMC Cancer 10:339.1-339.9(2010).
//
RX   PubMed=20593219; DOI=10.1007/s11060-010-0283-9;
RA   Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P.,
RA   Cairncross J.G.;
RT   "Effect of aberrant p53 function on temozolomide sensitivity of glioma
RT   cell lines and brain tumor initiating cells from glioblastoma.";
RL   J. Neurooncol. 102:1-7(2011).
//
RX   PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112;
RA   Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H.,
RA   Moncayo G., Hemmings B.A.;
RT   "MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta
RT   signaling pathway in human glioblastoma.";
RL   Cancer Res. 71:2392-2402(2011).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26496030; DOI=10.18632/oncotarget.6171;
RA   Patil V., Pal J., Somasundaram K.;
RT   "Elucidating the cancer-specific genetic alteration spectrum of
RT   glioblastoma derived cell lines from whole exome and RNA sequencing.";
RL   Oncotarget 6:43452-43471(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27412690; DOI=10.1074/mcp.M116.060350;
RA   Shraibman B., Kadosh D.M., Barnea E., Admon A.;
RT   "Human leukocyte antigen (HLA) peptides derived from tumor antigens
RT   induced by inhibition of DNA methylation for development of
RT   drug-facilitated immunotherapy.";
RL   Mol. Cell. Proteomics 15:3058-3070(2016).
//
RX   PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853;
RA   Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.;
RT   "Origin of the U87MG glioma cell line: good news and bad news.";
RL   Sci. Transl. Med. 8:354re3.1-354re3.4(2016).
//
RX   PubMed=27894925; DOI=10.1016/j.bbagen.2016.11.033;
RA   Casasampere M., Ordonez Y.F., Casas J., Fabrias G.;
RT   "Dihydroceramide desaturase inhibitors induce autophagy via
RT   dihydroceramide-dependent and independent mechanisms.";
RL   Biochim. Biophys. Acta 1861:264-275(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=33385022; DOI=10.1016/j.dib.2020.106643;
RA   de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G.,
RA   Silva W.A., Valente V.;
RT   "RNA sequencing data of different grade astrocytoma cell lines.";
RL   Data Brief 34:106643.1-106643.13(2021).
//